Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Non-Current Deffered Revenue (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Non-Current Deffered Revenue data on record, last reported at $15.8 million in Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 44.33% year-over-year to $15.8 million; the TTM value through Dec 2025 reached $15.8 million, down 44.33%, while the annual FY2025 figure was $15.8 million, 44.33% down from the prior year.
  • Non-Current Deffered Revenue reached $15.8 million in Q4 2025 per CCCC's latest filing, down from $19.9 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $50.9 million in Q1 2021 and bottomed at $15.8 million in Q4 2025.
  • Average Non-Current Deffered Revenue over 5 years is $24.5 million, with a median of $20.9 million recorded in 2024.
  • Peak YoY movement for Non-Current Deffered Revenue: tumbled 62.62% in 2022, then skyrocketed 45.99% in 2024.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $24.4 million in 2021, then tumbled by 30.67% to $16.9 million in 2022, then increased by 29.12% to $21.8 million in 2023, then soared by 30.45% to $28.5 million in 2024, then tumbled by 44.33% to $15.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $15.8 million in Q4 2025, $19.9 million in Q3 2025, and $21.2 million in Q2 2025.